Please login to the form below

Not currently logged in
Email:
Password:

ado-trastuzumab emtansine

This page shows the latest ado-trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

NICE relents on Kadcyla after Roche pricing negotiations

NICE relents on Kadcyla after Roche pricing negotiations

The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that

Latest news

  • A new decade of disruption: meeting the biosimilar challgenge A new decade of disruption: meeting the biosimilar challgenge

    High price tags have seen a string of rejections for routine NHS use by the UK watchdog NICE, including cancer MAbs Avastin (bevacizumab), Kadcyla (ado-trastuzumab emtansine) and Perjeta (pertuzumab). ... An example can be seen in Roche’s introduction

  • Roche says Tecentriq Roche says Tecentriq "off to a good start"

    Strong gains for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) reinforced a 5% increase for HER2 stalwart Herceptin (trastuzumab) to 3.4bn francs.

  • NHS patients set to be denied Opdivo and Kadcyla NHS patients set to be denied Opdivo and Kadcyla

    Kadycla discounts insufficient. Meanwhile, NICE's final rejection of Kadcyla (ado-trastuzumab emtansine) comes despite Roche offering undisclosed discounts on the drug's £90, 000-a-year list price, and after

  • Roche pharma sales strong for first half of 2015 Roche pharma sales strong for first half of 2015

    Its ageing breast cancer drug Herceptin (trastuzumab) and multi-cancer licensed Avastin (bevacizumab) were both a close second, recording identical sales of CHF3.26bn, up 11% and 9% respectively. ... New drugs impress. Revenue for its new range of newer

  • NHS names drugs to be re-evaluated for Cancer Drugs Fund NHS names drugs to be re-evaluated for Cancer Drugs Fund

    The re-evaluation could mean cancer patients in England are denied expensive new treatments like Roche's Kadycla (ado-trastuzumab emtansine) and Avastin (bevacizumab) if experts determine that their effectiveness does ... Kadcyla (trastuzumab emtansine).

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics